tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Bicycle Therapeutics (BCYC) and OrthoPediatrics (KIDS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intellia Therapeutics (NTLAResearch Report), Bicycle Therapeutics (BCYCResearch Report) and OrthoPediatrics (KIDSResearch Report) with bullish sentiments.

Intellia Therapeutics (NTLA)

JMP Securities analyst Silvan Tuerkcan reiterated a Buy rating on Intellia Therapeutics today and set a price target of $106.00. The company’s shares closed last Thursday at $65.43.

According to TipRanks.com, Tuerkcan is a 1-star analyst with an average return of -2.3% and a 36.1% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Crispr Therapeutics AG, and Logicbio Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intellia Therapeutics with a $108.53 average price target, which is a 75.3% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $163.00 price target.

See today’s best-performing stocks on TipRanks >>

Bicycle Therapeutics (BCYC)

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Bicycle Therapeutics, with a price target of $70.00. The company’s shares closed last Thursday at $25.36.

According to TipRanks.com, Benjamin has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -8.7% and a 34.7% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics.

Bicycle Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $57.43, which is a 153.2% upside from current levels. In a report issued on July 28, Barclays also initiated coverage with a Buy rating on the stock with a $30.00 price target.

OrthoPediatrics (KIDS)

JMP Securities analyst David Turkaly reiterated a Buy rating on OrthoPediatrics today and set a price target of $70.00. The company’s shares closed last Thursday at $53.97.

According to TipRanks.com, Turkaly is a 4-star analyst with an average return of 4.0% and a 46.6% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and Avanos Medical.

Currently, the analyst consensus on OrthoPediatrics is a Strong Buy with an average price target of $57.83, implying a 16.1% upside from current levels. In a report released yesterday, Needham also reiterated a Buy rating on the stock with a $59.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NTLA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More